Mannkind MNKD Furoscix — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Mannkind in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Mannkind’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mannkind's furoscix — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mannkind's furoscix — revenue?
- Mannkind (MNKD) reported furoscix — revenue of $15.49M in Q1 2026.
- How has Mannkind's furoscix — revenue changed year-over-year?
- Mannkind's furoscix — revenue increased by 167.4% year-over-year, from $5.79M to $15.49M.
- What does furoscix — revenue mean?
- This metric represents the total gross revenue generated from the sale of the Furoscix product line, excluding any taxes collected from customers. It serves as a primary indicator of market adoption and commercial performance for this specific therapeutic asset. Tracking this revenue stream allows investors to evaluate the growth trajectory and commercial viability of the product within the company's broader biopharmaceutical portfolio.